A Phase I Open-Label Study to Determine the Relative Bioavailability of GDC-0134 and to Investigate the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Subjects of Non-childbearing Potential

Trial Profile

A Phase I Open-Label Study to Determine the Relative Bioavailability of GDC-0134 and to Investigate the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Subjects of Non-childbearing Potential

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs GDC 0134 (Primary) ; Rabeprazole
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 16 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 04 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top